Related Experiment Video
Updated: Jul 19, 2026
05:19
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
Published on: November 7, 2025
Alternative technologies in cervical cancer screening: a randomised evaluation trial.
Ahti Anttila1, Matti Hakama, Laura Kotaniemi-Talonen
1Mass Screening Registry, Finnish Cancer Registry, Liisankatu 21 B, FI-00170 Helsinki, Finland. ahti.anttila@cancer.fi
BMC Public Health
|October 18, 2006
Summary
Improving cervical cancer screening with new technologies like HPV testing can prevent more deaths. Large trials are key to evaluating these advancements for better public health outcomes.
Area of Science:
- Public Health
- Gynecologic Oncology
- Screening Technologies
Background:
- Cervical cancer screening programs have significantly decreased disease incidence and mortality.
- Further reductions in cervical cancer deaths are possible through organized screening or program enhancements.
Purpose of the Study:
- To evaluate the renewal of the Finnish cervical cancer screening program using emerging technological alternatives.
- To assess screening effectiveness by monitoring subsequent cancers and screen-detected pre-cancers.
Main Methods:
- A randomized evaluation trial design integrated into the Finnish cervical cancer screening program.
- Approximately 863,000 women were allocated to automation-assisted cytology, human papillomavirus (HPV) DNA testing, or conventional cytology.
- Follow-up results on subsequent cervical cancers are expected between 2007 and 2015.
Main Results:
- Data collection ongoing for subsequent cervical cancer outcomes (2007-2015).
- Comparison of screening effectiveness between automation-assisted cytology, HPV DNA testing, and conventional cytology.
Conclusions:
- Large-scale randomized trials are essential for clarifying the effectiveness of technological alternatives in cervical cancer screening.
- Cost-effectiveness evaluations of new screening technologies are crucial for optimizing public health interventions.